Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | Larisa Umnova | - |
dc.contributor.advisor | Natālija Nikrus | - |
dc.contributor.author | Jekaterina Pirkina | - |
dc.contributor.other | Farmācijas fakultāte | lv-LV |
dc.contributor.other | Faculty of Pharmacy | en-UK |
dc.date.accessioned | 2023-02-15T22:22:48Z | - |
dc.date.available | 2023-02-15T22:22:48Z | - |
dc.date.issued | 2023 | - |
dc.identifier.uri | https://dspace.rsu.lv/jspui/handle/123456789/10542 | - |
dc.description | Klīniskā farmācija | lv-LV |
dc.description | Clinical Pharmacy | en-UK |
dc.description | Veselības aprūpe | lv-LV |
dc.description | Health Care | en-UK |
dc.description.abstract | Kopš 2020. gada pasaule dzīvo COVID-19 pandēmijas apstākļos. Pašlaik pasaulē ir reģistrēti vairāk kā 600 miljoni COVID-19 infekcijas gadījumu, pēc PVO 2022. gada decembra datiem nomira vairāk kā 6,5 miljonu cilvēku [1]. Bet neskatoties uz globālu pandēmiju, cilvēkiem ir blakusslimības, piemēram, koronārā sirds slimība, kas Latvijā joprojām ir viens no biežākajiem nāves cēloņiem [2], [3]. Ir zināms, ka zema blīvuma lipoproteīnu holesterīna līmenis ir viens no koronārās sirds slimības riska faktoriem, bet nav zināms, kā tas ietekmē uz COVID-19 slimības gaitu, smagumu un iznākumu . Šobrīd Latvijā ir nav pietiekami daudz datu par šī darba tēmu. Šī retrospektīva pētījuma mērķis bija noskaidrot saistību starp zema blīvuma lipoproteīnu holesterīna līmeni un Covid-19 slimības smagumu un iznākumu. Latvijas slimnīcās arhīvos tika analizētas COVID-19 pozitīvo pacientu slimības vēstures ar laboratoriski noteiktu zema blīvuma lipoproteīnu holesterīnu. Pētījuma laikā netika atrasta korelācija starp zema blīvuma lipoproteīnu holesterīna līmeni un COVOD-19 slimības smagumu un iznākumu. Tomēr izdevās pierādīt, ka pacientiem ar lieko ķermeņa svaru, paaugstinātu triglicerīdu līmeni bija smagāka COVID-19 slimības gaita. Analizējot COVID-19 slimības smagumu ar laboratoriskiem rādītājiem, tika konstatēta pozitīva korelācijas starp COVID-19 slimības smaguma pakāpi un D – dimēriem, fibrinogēnu, ALAT un CRO. | lv-LV |
dc.description.abstract | From 2020 the world is living under the conditions of COVID-19 pandemic. Currently, more than 600 million cases of COVID-19 infection have been registered in the world, according to WHO data from December 2022, more than 6.5 million people died [1]. But despite the global pandemic, people have co-morbidities, such as coronary heart disease, which is still one of the most common causes of death in Latvia [2], [3]. Low-density lipoprotein cholesterol is known to be one of the risk factors for coronary heart disease, but how this affects the course, severity, and outcome of COVID-19 is unknown. Currently, there is not enough data on the topic of this work in Latvia. The main purpose of this retrospective study was to find a relationship between low-density lipoprotein cholesterol and the severity and outcome of COVID-19 disease. The medical histories of COVID-19 positive patients with laboratory-determined low-density lipoprotein cholesterol levels were analyzed in Latvian hospital archives. The results of the study show that low-density lipoprotein cholesterol levels were not associated with disease severity and outcome of COVID-19. At the same time, it was found that in patients with overweight, elevated triglyceride levels, the course of COVID-19 disease was more severe. Analyzing the severity of the disease of COVID-19 with laboratory indicators, positive correlations were found between the severity of the disease of COVID-19 and D-dimers, fibrinogen, ALAT and CRP. | en-UK |
dc.language.iso | lv-LV | - |
dc.publisher | Rīgas Stradiņa universitāte | lv-LV |
dc.publisher | Rīga Stradiņš University | en-UK |
dc.rights | info:eu-repo/semantics/restrictedAccess | - |
dc.subject | COVID-19 infekcija | lv-LV |
dc.subject | koronārā sirds slimība | lv-LV |
dc.subject | dislipidēmija | lv-LV |
dc.subject | zema blīvuma lipoproteīna holesterīns | lv-LV |
dc.subject | retrospektīvs pētījums | lv-LV |
dc.subject | COVID-19 infection | en-UK |
dc.subject | coronary heart disease | en-UK |
dc.subject | dyslipidaemia | en-UK |
dc.subject | low-density lipoprotein cholesterol | en-UK |
dc.subject | retrospective study | en-UK |
dc.title | Saistība starp zema blīvuma lipoproteīnu holesterīna līmeni un Covid-19 slimības smagumu un iznākumu. | lv-LV |
dc.title.alternative | Relationship between low-density lipoprotein cholesterol and the severity and outcome of COVID-19 disease | en-UK |
dc.type | info:eu-repo/semantics/masterThesis | en-UK |
Appears in Collections: | Maģistra darbi |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Pētījumu ētikas komitejas lēmums_Jekaterina Pirkina.pdf | Noslēguma darba pielikums | 135.5 kB | Adobe PDF | View/Open Request a copy |
Farmacijas_fakultate_FFMp_2023_Jekaterina_Pirkina_005533.pdf | Maģistra darbs | 1.3 MB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.